Search research articles
Contact Us
Filters
Showing results (91-100 of 112) with videos related to
Page
of 12
Sort By:
Journal for Immunotherapy of Cancer
|
January 23, 2018
Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Aly-Khan A Lalani, Wanling Xie, Dylan J Martini, et al.
Cancer Medicine
|
February 27, 2020
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
Julie M Shabto, Dylan J Martini, Yuan Liu, et al.
Cancer
|
July 3, 2024
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation
Dylan J Martini, Katherine B Case, Derrik Gratz, et al.
Journal of Immunotherapy and Precision Oncology
|
August 29, 2022
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
Dylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist
|
February 26, 2021
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors
Jacqueline T Brown, Yuan Liu, Julie M Shabto, et al.
Frontiers in Oncology
|
July 5, 2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
T Anders Olsen, Dylan J Martini, Subir Goyal, et al.
Clinical Genitourinary Cancer
|
December 19, 2021
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients
Dylan J Martini, Sean T Evans, Yuan Liu, et al.
Cancer Immunology Research
|
February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Dylan J Martini, Lana Hamieh, Rana R McKay, et al.
Frontiers in Oncology
|
July 26, 2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
Dylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist
|
June 7, 2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors
Gregory E Sanda, Julie M Shabto, Subir Goyal, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 112) with videos related to
Sort By:
Page
of 12
Journal for Immunotherapy of Cancer
|
January 23, 2018
Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Aly-Khan A Lalani, Wanling Xie, Dylan J Martini, et al.
Cancer Medicine
|
February 27, 2020
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
Julie M Shabto, Dylan J Martini, Yuan Liu, et al.
Cancer
|
July 3, 2024
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation
Dylan J Martini, Katherine B Case, Derrik Gratz, et al.
Journal of Immunotherapy and Precision Oncology
|
August 29, 2022
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
Dylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist
|
February 26, 2021
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors
Jacqueline T Brown, Yuan Liu, Julie M Shabto, et al.
Frontiers in Oncology
|
July 5, 2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
T Anders Olsen, Dylan J Martini, Subir Goyal, et al.
Clinical Genitourinary Cancer
|
December 19, 2021
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients
Dylan J Martini, Sean T Evans, Yuan Liu, et al.
Cancer Immunology Research
|
February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Dylan J Martini, Lana Hamieh, Rana R McKay, et al.
Frontiers in Oncology
|
July 26, 2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
Dylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist
|
June 7, 2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors
Gregory E Sanda, Julie M Shabto, Subir Goyal, et al.
Page
of 12